May 4, 2022
May 4, 2022
Boonton, NJ, May 4, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
April 12, 2022
April 12, 2022
Boonton, NJ, April 12, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
April 4, 2022
April 4, 2022
Article describes unique features of Enteris’ Peptelligence® and ProPerma® peptide and small molecule oral delivery technology Boonton, NJ, April 4, 2022 — Enteris BioPharma, Inc., a biotechnology […]
March 7, 2022
March 7, 2022
Paper examines barriers to achieving optimal content uniformity with HPAPIs and the techniques manufacturers should use with low-dose drug products. Boonton, NJ, March 7, 2022 — Enteris […]
March 1, 2022
March 1, 2022
Boonton, NJ, March 1, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
February 15, 2022
February 15, 2022
Six feasibility programs underway for oral tablet formulations developed with Enteris’ Peptelligence® and ProPerma® technology platforms Boonton, NJ, February 15, 2022 — Enteris BioPharma, Inc., a biotechnology […]
January 10, 2022
January 10, 2022
Boonton, NJ, January 10, 2022 — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
KNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MOREKNOWLEDGE CENTER
Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.
LEARN MORE
